The medical therapy for cerebellar mutism syndrome: a case report and literature review.
Cerebellar dysfunction
Mutism
Pharmacological therapy
Posterior fossa surgery
Journal
Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
ISSN: 1433-0350
Titre abrégé: Childs Nerv Syst
Pays: Germany
ID NLM: 8503227
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
29
03
2021
accepted:
26
05
2021
pubmed:
16
6
2021
medline:
16
9
2021
entrez:
15
6
2021
Statut:
ppublish
Résumé
Cerebellar mutism syndrome (CMS) represents a major complication affecting many children that undergo surgery for posterior fossa lesions. Etiology and pathophysiology are still not fully understood. CMS deeply influences quality of life and recovery of these patients. An effective treatment has not been defined yet. This case-based review aims at analyzing the available evidence and knowledge to better delineate this phenomenon and to determine whether CMS can be successfully treated with pharmacological therapy. Systematic research and retrieval of databases were conducted analyzing all papers where medical treatment of CMS was reported. A summary of the latest understanding and reports regarding definition, clinical manifestations, pathophysiology, management, and outcome of CMS has been conducted. Consensus on definition of this syndrome is lacking. CMS is the term accepted by the Posterior Fossa Society in 2016. Pathophysiology is still poorly understood but the most likely mechanism is injury along proximal components of the efferent cerebellar pathway. Nine papers describing positive effects of pharmacological therapy for CMS have been identified. Fluoxetine, zolpidem, bromocriptine, and midazolam are the drugs that seem to alleviate symptoms of CMS and improve recovery. To date, cognitive rehabilitation and physiotherapy are the only treatment options available. CMS has deep impact on affected children and their families. Despite attempts to identify preventive measures and treatment, cases still occur on a regular basis. Pharmacological treatments have been proposed to help reduce the symptoms of CMS with some promising results, but reports are limited; therefore, further studies are needed.
Identifiants
pubmed: 34128119
doi: 10.1007/s00381-021-05233-5
pii: 10.1007/s00381-021-05233-5
doi:
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2727-2734Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Sergeant A K-SM, Manoranjan B, Karmur B, Duckworth J, Petrelli T, Savage K, Ajani O, Yarascavitch B, Samaan MC, Scheinemann K, Alyman C, Almenawer S, Farrokhyar F, Fleming AJ, Singh SK, Stein N (2017) Analysis of surgical and MRI factors associated with cerebellar mutism. J Neurooncol 133:539–52
Gadgil NHD, Barry J, Chang R (2016) Lang S Posterior fossa syndrome in children following tumor resection: knowledge update. Surg Neurol Int 7:S179–S183
doi: 10.4103/2152-7806.178572
Gudrunardottir TSA, Juhler M, Schmiegelow K (2010) Cerebellar mutism: review of the literature. Childs Nerv Syst 27:355–363
doi: 10.1007/s00381-010-1328-2
Amor-Garcia MA, Fernandez-Llamazares CM, Manrique-Rodriguez S et al (2020) Bromocriptine for the treatment of postoperative cerebellar mutism syndrome in pediatric patients: three case reports. J Oncol Pharm Pract :1078155220982046. https://doi.org/10.1177/1078155220982046 [published Online First: 2020/12/29]
Catsman-Berrevoets C, Patay Z (2018) Cerebellar mutism syndrome. Handb Clin Neurol 155:273–288. https://doi.org/10.1016/B978-0-444-64189-2.00018-4[publishedOnlineFirst:2018/06/13]
doi: 10.1016/B978-0-444-64189-2.00018-4[publishedOnlineFirst:2018/06/13]
pubmed: 29891065
Schmahmann JD (2020) Pediatric post-operative cerebellar mutism syndrome, cerebellar cognitive affective syndrome, and posterior fossa syndrome: historical review and proposed resolution to guide future study. Childs Nerv Syst 36(6):1205–1214. https://doi.org/10.1007/s00381-019-04253-6[publishedOnlineFirst:2019/06/27]
doi: 10.1007/s00381-019-04253-6[publishedOnlineFirst:2019/06/27]
pubmed: 31240391
Thompson EM, Hielscher T, Bouffet E, Remke M, Luu B, Gururangan S, McLendon RE, Bigner DD, Lipp ES, Perreault S, Cho YJ, Grant G, Kim SK, Lee JY, Rao AAN, Giannini C, Li KKW, Ng HK, Yao Y, Kumabe T, Tominaga T, Grajkowska WA, Perek-Polnik M, Low DCY, Seow WT, Chang KTE, Mora J, Pollack IF, Hamilton RL, Leary S, Moore AS, Ingram WJ, Hallahan AR, Jouvet A, Fèvre-Montange M, Vasiljevic A, Faure-Conter C, Shofuda T, Kagawa N, Hashimoto N, Jabado N, Weil AG, Gayden T, Wataya T, Shalaby T, Grotzer M, Zitterbart K, Sterba J, Kren L, Hortobágyi T, Klekner A, László B, Pócza T, Hauser P, Schüller U, Jung S, Jang WY, French PJ, Kros JM, van Veelen MC, Massimi L, Leonard JR, Rubin JB, Vibhakar R, Chambless LB, Cooper MK, Thompson RC, Faria CC, Carvalho A, Nunes S, Pimentel J, Fan X, Muraszko KM, López-Aguilar E, Lyden D, Garzia L, Shih DJH, Kijima N, Schneider C, Adamski J, Northcott PA, Kool M, Jones DTW, Chan JA, Nikolic A, Garre ML, Van Meir EG, Osuka S, Olson JJ, Jahangiri A, Castro BA, Gupta N, Weiss WA, Moxon-Emre I, Mabbott DJ, Lassaletta A, Hawkins CE, Tabori U, Drake J, Kulkarni A, Dirks P, Rutka JT, Korshunov A, Pfister SM, Packer RJ, Ramaswamy V, Taylor MD (2016) Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncol 17(4):484–495
doi: 10.1016/S1470-2045(15)00581-1
Catsman-Berrevoets CE (2017) Cerebellar mutism syndrome: cause and rehabilitation. Curr Opin Neurol 30(2):133–139. https://doi.org/10.1097/WCO.0000000000000426[publishedOnlineFirst:2017/01/25]
doi: 10.1097/WCO.0000000000000426[publishedOnlineFirst:2017/01/25]
pubmed: 28118304
Robertson PLMK, Holmes EJ, Sposto R, Packer RJ, Gajjar A, Dias MS (2006) Allen JC Incidence and severity of postoperative cerebellar mutism syndrome in children with medulloblastoma: a prospective study by the Children’s Oncology Group. J Neurosurg 105:444–451
pubmed: 17184075
Pollack I (1997) Posterior fossa syndrome. Int Rev Neurobiol 41:411–432
doi: 10.1016/S0074-7742(08)60362-1
Gudrunardottir T, Morgan AT, Lux AL et al (2016) Consensus paper on post-operative pediatric cerebellar mutism syndrome: the Iceland Delphi results. Childs Nerv Syst 32(7):1195–1203. https://doi.org/10.1007/s00381-016-3093-3[publishedOnlineFirst:2016/05/05]
doi: 10.1007/s00381-016-3093-3[publishedOnlineFirst:2016/05/05]
pubmed: 27142103
Schmahmann JD SJ (1997) The cerebellar cognitive affective syndrome. In: Schmahmann JD (ed) IRN, ed. The cerebellum and cognition San Diego Academic Press :433–40
Reed-Berendt R PB, Picton, Chumas P, Warren D, Livingston JH, Hughes E, Morrall MCHJ (2014) Cause and outcome of cerebellar mutism: evidence from a systematic review. Childs Nerv Syst 30(3):375–85
Black BUT (1994) Treatment of elective mutism with fluoxetine: a double blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry 33:1000–1006
doi: 10.1097/00004583-199409000-00010
Dummit ESKR, Tancer NK, Asche B (1996) Martin J Fluoxetine treatment of children with selective mutism: an open trial. J Am Acad Child Adolesc Psychiatry 35:615–621
doi: 10.1097/00004583-199605000-00016
Akhaddar ASM, El Asri AC (2012) Boucetta M Treatment of postoperative cerebellar mutism with fluoxetine. Childs Nerv Syst 28:507–508
doi: 10.1007/s00381-012-1719-7
El-Nabbout BHDG (2002) Treatment of cerebellar mutism with fluoxetine: report on two patients. Annal Neurol 52(3):S161
Shyu CBK, Souweidane MM, Dunkel IJ, Gilheeney SW, Gershon T (2011) Khakoo Y Novel use of zolpidem in cerebellar mutism syndrome. J Pediatr Hematol Oncol 33:148–149
doi: 10.1097/MPH.0b013e3182053a1a
Adachi JNR, Hirose T (2005) Matsutani M Mixed neuronal-glial tumor of the fourth ventricle and successful treatment of postoperative mutism with bromocriptine: case report. Surg Neurol 63:375–379
doi: 10.1016/j.surneu.2004.05.039
Arevalo-Saenz A P-SMaSR (2017) Bromocriptina: podria ser la cura Para el mutismo acinetico posquirurgico? [bromocriptine: could it be the cure for post-surgical akinetic mutism?]. Rev Neurol 64:70–74
Gudrunardottir T, Sehested A, Juhler M et al (2011) Cerebellar mutism: definitions, classification and grading of symptoms. Childs Nerv Syst 27(9):1361–1363. https://doi.org/10.1007/s00381-011-1509-7[publishedOnlineFirst:2011/07/07]
doi: 10.1007/s00381-011-1509-7[publishedOnlineFirst:2011/07/07]
pubmed: 21732118
Caner HAN, Benli S, Calişaneller T, Albayrak A (1999) Akinetic mutism after fourth ventricle choroid plexus papilloma: treatment with a dopamine agonist. Surg Neurol 51:181–184
doi: 10.1016/S0090-3019(98)00120-7
Catsman-Berrevoets CEVDH (1992) Zwetsloot CP Transient loss of speech followed by dysarthria after removal of posterior fossa tumour. Dev Med Child Neurol 32:1102–1109
Echiverri HCTW, Merens TA, Coker SB (1988) Akinetic mutism: pharmacologic probe of the dopaminergic mesencephalofrontal activating system. Pediatr Neurol 4:228–230
doi: 10.1016/0887-8994(88)90036-7
Mateo-Sierra O GeF, Fernandez-Carballal C, Pinilla D, Mosqueira B, Iza B, Carrillo R (2005) Mutismo acinetico relacionado con hidrocefalia y cirugıa cerebelosa tratado con bromocriptina y efedrina. Revision fisiopatologica [akinetic mutism related to hydrocephalus and cerebellar surgery treated with bro- mocriptine and ephedrine. A pathophysiological review]. Neurocirugia (Astur) 16:134–41; discussion 41
Nicita FPM, Liberatore M, Spalice A, Papoff P, Ullo M, Piccirilli M, Clerico A, Schiavetti A (2017) Sudden benzodiazepine-induced resolution of post-operative pediatric cerebellar mutism syndrome: a clinical-SPECT study. Acta Neurochir 159:475–479
doi: 10.1007/s00701-016-3059-y
Miller NGRW, Kocak M, Glass JO, Löbel U, Morris B, Gajjar A, Patay Z (2010) Cerebellocerebral diaschisis is the likely mechanism of postsurgical posterior fossa syndrome in pediatric patients with midline cerebellar tumors. AJNR Am J Neuroradiol 31:288–294
doi: 10.3174/ajnr.A1821
Mortimer D (2011) Clinical case study: a 4-year-old boy with posterior fossa syndrome after resection of a medulloblastoma. J Neurosci Nurs 43:225–229
doi: 10.1097/JNN.0b013e3182212af9
Roka YBSM (2011) Aryal S Cerebellar mutism after pineal tumour excision: a case report 124–126. J Nepal Paediatr Soc 31:124–126
doi: 10.3126/jnps.v31i2.4167
Walker D, Thomas SA, Talbot EJ et al (2014) Cerebellar mutism: the rehabilitation challenge in pediatric neuro-oncology: case studies. J Pediatr Rehabil Med 7(4):333–340. https://doi.org/10.3233/PRM-140309[publishedOnlineFirst:2014/12/31]
doi: 10.3233/PRM-140309[publishedOnlineFirst:2014/12/31]
pubmed: 25547885
Suzman KMR, Morris M (1997) Milan M Cognitive behavioral remediation of problem solving deficits in children with acquired brain injury. J Behav Ther Exp Psychiatry 28:203–212
doi: 10.1016/S0005-7916(97)00023-2
Steinbok P, Cochrane DD, Perrin R et al (2003) Mutism after posterior fossa tumour resection in children: incomplete recovery on long-term follow-up. Pediatr Neurosurg 39:179–183
doi: 10.1159/000072468
Mei C, Morgan AT (2011) Incidence of mutism, dysarthria and dysphagia associated with childhood posterior fossa tumour. Childs Nerv Syst 27:1129–1136
doi: 10.1007/s00381-011-1433-x
Palmer SL, Hassall T, Evankovich K et al (2010) Neurocognitive outcome 12 months following cerebellar mutism syndrome in pediatric patients with medulloblastoma. Neuro Oncology 12:1311–1317
pubmed: 20713408
pmcid: 3018935
Catsman-Berrevoets CE, Aarsen FK (2010) The spectrum of neurobehavioural deficits in the posterior fossa syndrome in children after cerebellar tumour surgery. Cortex 46:933–946
doi: 10.1016/j.cortex.2009.10.007
Rekate HLGR, Aram DM, Hahn JF, Ratcheson RA (1985) Muteness of cerebellar origin. Arch Neurol 42:697–698
doi: 10.1001/archneur.1985.04060070091023